Diagnos Five Years Ahead of Google in Diabtetic Retinopathy Screening Says Harvard Professor
Diabetic Retinopathy Market Predicted to Hit US$10.11 Billion by 2022
Diagnos Launches Hypertension Screening Application
AI Healthcare Applications Expected to Grow at 52% CAGR Between 2017-2022, Hitting US$7.98 Billion
Momentum Public Relations
Blog: September 24, 2018
On September 14th, 2018 Diagnos (TSXV: ADK) held an investor presentation at a downtown Montreal bistro for retail and institutional investors. Diagnos’ flagship product is CARA, computer aided retinal analysis, a cost efficient diabetic retinopathy screening application running on the company’s artificial intelligence platform Flaire. The company has been going from triumph to triumph this year. One indication of that was the presence of Chinese investment fund representatives.
During the presentation, recently appointed Diagnos Board member Dr. Reed Maclellan described the company’s technology as being “light years ahead of the competition. I was at a recent conference and nobody, not even Google can do what Cara can. Cara can detect macular degeneration. This is the only technology in the world that can do it. Diagnos is five years ahead of Google.”
Maclellan is an adjunct professor at both Harvard and the Boston Children’s Hospital where he teaches surgery. A microcirculation specialist, Dr. Maclellan also lectures internationally and frequently speaks at conferences of the American College of Surgeons, the Plastic Surgeons Research Council and the International Society of Vascular Anomalies.
Diagnos develops screening tools that help health care providers cut costs and make early diagnoses. Cara is designed to detect diabetic retinopathy and has the potential to prevent 85-90% of diabetes induced vision loss through early detection. At last count Cara has screened 222,034 patients, in 16 countries, using 131 screening sites. If untreated diabetic retinopathy leads to blindness.
The company is currently conducting its first Canadian pilot project in Montreal at CHUM, the Centre hospitalier de l’Universite de Montreal. If the pilot project is a success, Larente expects to be setting up Cara screening centres in hospitals and clinics across Quebec. CHUM has 35,000 diabetics, 80% of whom have never had a retina screening. Once you are a diabetic you face a 50% chance of going blind.
“Our job,” Larente, Diagnos’ president said in an earlier interview, “is to screen those 35,000 diabetics and send the ones that are critical right to the ophthalmology department and mange the other ones. Manage means you come every year and you get your test done.”
Once the pilot project is completed Larente expects to see Cara screening facilities in Quebec hospitals and just as a successful pilot project in Mexico led to a government contract, he expects the CHUM pilot project to result in a contract with the Quebec Ministry of Health.
“This will actually reduce the cost to the government because now you are going to manage the diabetic population. When you start to have retinopathy you can treat the patient. There is diet, there are vitamins. There are small inexpensive treatments to make sure it doesn’t go to the critical stage. There is a very effective laser treatment for bleeding.”
The diabetic retinopathy market is growing at 6.8% CAGR and according to a news release issued by Million Insights will grow from US$5.9 billion in 2014, to US$10.11 billion in 2022.
During the presentation, Diagnos president Andre Larente, announced that while the company intended to keep on marketing to government health agencies it also intended to beef up its approach to targets like hospitals and health care providers.
Drawing on his own experience, Maclellan described why AI powered medical devices had an initial slow adoption rates. “People were afraid it would take their jobs.” That has now changed. “Once one hospital starts using it, Cara adoption will snowball.”
To show just how much AI driven platforms are gaining traction in medicine at the beginning of 2018 Research House Frost & Sullivan predicted that by 2025, 85% of surgical procedures are likely to be done by robots.
According to Market and Markets, the market for artificial intelligence applications in healthcare will grow from US$667.1 million in 2016 to US$ 7.98 billion in 2022, growing at a CAGR of 52.68% during the forecast period.
Diagnos’ product line is expanding. In July the company launched the first application in its Cardio product line, Cara HTA. The application uses the same fundus camera used for diabetic retinopathy to screen for hypertensive retinopathy. Cara HTA also monitors the efficacy of blood pressure treatments which will allow doctors to monitor and adjust treatment as necessary.
From a revenue standpoint, Cara HTA offers the same form of recurring revenues that screening for diabetic retinopathy does. Once the screening has been initially performed patients will require additional screenings on an annual or as needed basis.
The hypertension market is huge. Almost one in two adult Americans, for example, suffer from high blood pressure, a precursor to strokes and heart attacks.
Diagnos also has a third product in development, Cara Cardio which will screen for cardiovascular disease and debut during 2019. In September Diagnos signed two agreements. The first was with another Montreal-based company Optina Diagnostics, to provide a telemedicine platform based on Cara for a period of three years. Optina will use Diagnos Cloud Services to upload images generated by Optina’s hyperspectral camera for the early detection of Alzheimer’s.
The company believes that the agreement will attract other biotech companies that need a telemedicine platform. Cara includes a telemedicine platform that allows all the medical professionals involved to see the same picture. Additionally the company has already successfully incorporated blockchain technology to maintain patient confidentiality.
In September the company also signed a three year agreement with American company 20/20NOW to provide diabetic retinopathy screening services. 20/20NOW is a pioneer in ocular telehealth.
September has been a good month for Diagnos, the future should be even better.
- Published in Blog, Diagnos, Life Sciences, News Home, Technology, Uncategorized
DIAGNOS to Provide Retinal Image Analysis using its AI Technology to 20/20NOW, the Leading Ocular Telehealth Provider in the United States
Momentum Public Relations
Press Release: September 18, 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today a three-year agreement to provide its CARA (Computer Assisted Retina Analysis) to 20/20NOW. 20/20NOW will use CARA to upload their retinal images and retrieve the results after analysis by our algorithms to detect anomalies caused by diabetic retinopathy in real time. Identifying diabetic retinopathy (“DR”) in its early stages, when it’s most treatable, is critical to prevent blindness and help at lowering health care costs.
“At DIAGNOS, we’re pleased to welcome an innovative company, 20/20NOW, as a new customer and business partner. We also want to extend a warm welcome to their network of more than 60 customers located across the United States. We will exclusively provide rapid and early detection of DR to their customers in the optical space. As 20/20NOW expands their network, we will provide them with fast and reliable detection of DR. As we introduce new healthcare applications, we will work with 20/20NOW to leverage their network and provide early detection of other illnesses to the benefit of their patients.” said Yves-Stephane Couture, Vice-President of Sales at DIAGNOS.
Telehealth industry veteran and 20/20NOW CEO, Chuck Scott, stated “Our mission at 20/20NOW is to expand access to comprehensive eye exams while also improving the standard of care, at a lower cost to our patients. Through the use of cutting-edge AI technology provided by DIAGNOS, our Ocular Telehealth eye exams represent a cost-effective tool to help solve one of the most pressing health care issue in our country today.”
Mr. Scott further stated “The opportunity exists to combine the use of AI and Ocular Telehealth to cost effectively screen and detect other critical health diseases beyond diabetic retinopathy. We believe there will be a vast array of ocular diseases that can be detected through AI and retinal screenings in the future. We look forward to partnering with DIAGNOS to bring these capabilities to market.”
About 20/20NOW
20/20NOW is the pioneer and innovator of ocular telehealth. Using state-of-the-art technology, proprietary software and patented exam processes, 20/20NOW provides comprehensive eye exams, including eye health screenings, via telehealth. The company’s telehealth model allows eye care professionals and optical retailers to provide their patients with increased access to high quality eye exams at a lower cost.
Additional information is available at www.for2020now.com.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
- Published in Business, Diagnos, Life Sciences, News Home, Technology
DIAGNOS Partners with Optina Diagnostics, a Montreal Based Company, to Provide a Web Platform for the Early Detection of Alzheimer Disease
Momentum Public Relations
Press Release: September 5, 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an agreement to provide a telemedicine platform based on CARA (Computer Assisted Retina Analysis) to Optina Diagnostics (“Optina”) for a period of 3 years. Optina will use DIAGNOS Cloud services to upload images generated by Optina’s hyperspectral camera for early detection of Alzheimer via key biomarkers in the retina of the eye.
The processed images will be available to be shared and further analysed by healthcare professionals and clinics in various locations. Optina will benefit from the high throughput of DIAGNOS CARA Cloud service as well as the ease of use of the teleophthalmology platform currently used by doctors and other medical professionals.
“At DIAGNOS, we are extremely happy to contribute to the success of innovative Quebec companies like Optina. Optina will leverage our experience and the high quality standard of CARA, a field proven platform approved for sale by the Food and Drug Administration in the United States, Health Canada and other countries’ homologation bodies. This partnership will foster more collaboration with other biotech firms and attract new clients in need of a telemedicine platform.” said Yves-Stephane Couture, Vice-President of sales at DIAGNOS.
“The partnership will greatly accelerate Optina’s commercialization of its Alzheimer diagnostic test, saving critical time to market while providing effective and efficient user experience.” said David Lapointe, President and CEO of Optina.
About Optina
Optina Diagnostics is a Montreal based company focused on the development of technology for the early detection of disease through hyperspectral imaging of the eye. With a first application in the early diagnosis of Alzheimer’s, Optina brings a radiomics approach to biomarker detection.
Additional information about Optina is available at www.optinadx.com.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele- ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
- Published in Business, Diagnos, Life Sciences, News Home, Technology
DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants
Momentum Public Relations
Press Release: August 24, 2018
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 1,333,333 units (each a “Unit”) issued at $0.075 per Unit for gross proceeds of up to $100,000. Each Unit consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.10 per Share, for a period of 18 months from the date of issuance of the Warrant.
The proceeds will be used to fund marketing and administrative expenses.
Shares issued as part of the Private Placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period from the date of issuance.
Closing of the Private Placement is scheduled for August 30, 2018. The Private Placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Josh Falle |
DIAGNOS Inc. | Momentum PR |
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 |
alarente@diagnos.ca | josh@momentumpr.com |
- Published in Business, Diagnos, Life Sciences, News Home, Technology
DIAGNOS Provides Update on Business Operations
Momentum Public Relations
Press Release: July 31 2018
Diagnos Inc.(ADK:V) (DGNOF:OTCQB), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an update on business operations.
We are happy to report these important milestones and accomplishments over the last twelve months:
- Signing of our first agreement with a Canadian hospital, the CHUM in Montreal. This hospital is now screening patients for diabetic retinopathy and hypertension. We expect to screen 4,500 patients from August to December of 2018. It is estimated that the diabetic population in Quebec is 800,000,
- Signing of a 3-year contract with our first customer in the USA after a successful pilot. We are currently screening an average of 600 patients per month and our customer is ordering additional cameras,
- First contract in Saudi Arabia with a local partner. We began with 100 patients screened per month and now we are averaging 1,000 per month,
- Working with pharmaceutical companies such as Novo Nordisk to broaden the use of our AI technology for the detection of Hypertension complications in the retina of the eye,
- Opening of our first of 15 clinics in Panama and a new provincial government state in Mexico. We have several new proposals in Latin America with many governments and clinics.
- Establishing a sales force to cover Latin America and the USA including existing international accounts. The Mexican government has temporarily stopped the mass screening program because of elections in Mexico. Now that the election results are known, we plan to restart the program soon.
CARDIO, our new Hypertension application announced recently, is a by-product of the work we are doing in the field of stroke prevention based on the analysis of the human vascular system. This new prevention tool is in clinical trial in the US, Canada, Algeria and Mexico. We are working with other hospitals and we expect to see more organisations collaborating with DIAGNOS in the development of CARDIO.
The Corporation is working at establishing a permanent team to cover the US market. The addition of a new US based board member, Dr. Reid Maclellan, is contributing to the business development efforts there. Dr. Maclellan, an Instructor of Surgery in the field of vascular anomalies at Harvard Medical School, will contribute to DIAGNOS’ growth in the US. Additionally we made changes at the board level in bringing new senior talent to improve corporate governance.
“The last year was a pivotal period for DIAGNOS. The AI market came alive in 2017. We believe this demonstrates that all the work done by our employees to become an early leader is finally benefiting the Corporation. For the last 2 years, DIAGNOS has been working with clients in 16 countries to establish a local presence and this proves that the use of AI in the medical field is really happening. In our opinion, the learning curve for any high tech company to be fully able to access the medical market is at least 5 years. We also strongly believe we’ve got the right timing with our AI solutions. Regulatory approvals such as FDA, Health Canada, CE mark, COFEPRIS plus others and the proof of concept have been successfully achieved at DIAGNOS,’’ said André Larente, President and CEO of DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele- ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle |
DIAGNOS Inc. | Momentum PR |
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 |
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
DIAGNOS Installs its First Retina Screening Clinic based on Artificial Intelligence in Panama
Momentum Public Relations
Press Release: July 10 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the installation of its first retina AI screening clinic, in the Panama’s private health sector.
“We are delighted to open our first of 15 Medical clinics in Panama in collaboration with DIAGNOS,” said the CEO and owner of these clinics. He also added: “We encourage and support DIAGNOS in its endeavor as an AI pioneer in the early detection of critical health issues, such as diabetic retinopathy. We are also looking forward to the upcoming release of the hypertension application.”
“We are looking forward to a long term relationship with our new customer in Panama. We have been working with their team to establish a marketing strategy to support their growth objectives. We are anticipating a substantial growth in the number of patients to screen,” said Guillermo Moreno, Vice-President at DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tél. : 450 678-8882, poste 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
DIAGNOS Broadens its Collaboration with the Government of Mexico
Momentum Public Relations
Press Release: July 4 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX-V:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an expansion of its screening services with the Mexican government in one northern state of Mexico. As per the agreement, DIAGNOS plans to screen 10,000 patients by December 31, 2018.
“In Mexico, a large portion of our government’s budget and expenses is going towards the medical treatment of two major problems for our patients’ health; diabetes and hypertension. Our objective is to collaborate with DIAGNOS in order to provide a preventive and a better way of monitoring our patients health”, said the Chief Medical Officer of the state. The Chief Medical Officer of the state also added: “We strongly believe that this preventive approach will strongly benefit our patients and generate substantial savings in future healthcare costs”.
The project consists of the screening of 10,000 patients by December 31, 2018, with a vision to extend the project for the following years. “We have been working with the diabetes team at the state level, and are able to provide the right solution at the right time”, said Guillermo Moreno, Vice-President at DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tél. : 450 678-8882, poste 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
DIAGNOS Provides Financing Updates
Momentum Public Relations
Press Release: June 29 2018
DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIREplatform based on Artificial Intelligence (AI), provides updates on financing activities previously announced on June 14, 2018.
Private placement of units
The Corporation announces a new closing date of July 4th, 2018 in connection with the private placement of units (each a “Unit”) for gross proceeds of up to $1,200,000. Each Unit consists of:
- One Secured, Convertible and Redeemable Debenture (“Debenture”), 3-year term, 10% annual interest, principal of $50,000 per Debenture, and
- 200,000 stock warrants (each a “Stock warrant”) entitling the holder to purchase one common share (“Share”) per Warrant at a price of $0.15 per Share, for a period of 18 months from the date of issuance of the Stock warrant.
Private placement – shares
The Corporation announces the cancellation of , 800,000 units (each a “Share-unit”), for gross proceeds of $60,000, in connection with the $120,000 private placement of common shares and stock warrants. Each Share-unit consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.10 per Share, for a period of 18 months from the date of issuance of the Warrant.
The cancellation is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Mr. Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
DIAGNOS Announces the Availability of its New CARA High Blood Pressure Risk Assessment Based on its FLAIRE Artificial Intelligence Platform
Momentum Public Relations
Press Release: June 12 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the availability of its first cardio application called HTA. This innovative application of CARA’s platform provides an automated system analysis of the microcirculation for hypertensive patients. It provides an early warning of high blood pressure imbalance by evaluating the state of the circulation of the retina. This application is scheduled to be commercially available in July 2018 and uses the same cameras that are used for diabetic retinopathy screening.
“Following months of development in our Cardio product group, we are introducing the HTA application. The significance of hypertensive retinopathy will be measured by DIAGNOS algorithms. This new application may have great impact to further reduce cardiovascular morbidity and mortality, as demonstrated by several clinical reports and many previous studies. In fact, an assessment of hypertensive retinopathy is supported by international hypertension management guidelines, including the US Joint National Committee on Prevention Detection Evaluation, and Treatment of High Blood Pressure and the British Society of Hypertension.
Regression of hypertensive retinopathy signs with optimal control of blood pressure and adequate hypertension treatment, resolution of hypertensive retinopathy signs may occur over a period of 6 months. The new application will be able to measure and report the impact of the treatment on the state of the microcirculation to further assist medical professionals. This measurement is simple, low-cost, non-invasive and uses a commercially available fundus camera. At regular intervals, we can monitor the patients using the same test to reach best control of blood pressure and adequate hypertension treatment,” said Dr. Hadi Chakor, DIAGNOS Chief Medical Officer.
We often hear from physicians and healthcare insurers that DIAGNOS screening tests are very much needed to detect the early stages of micro vascular anomalies. High blood pressure, or hypertension, happens when blood pressure in the arteries is elevated if your blood pressure readings are consistently 139 over 89, or higher. Hypertension is often called “the silent killer” as it has no warning signs or symptoms, and can only be diagnosed through blood pressure measurement. It can affect anyone and is more common as we age. Once hypertension develops, it usually lasts for life. High blood pressure is the number one risk factor for stroke and a major risk factor for heart disease.
An estimated 103 million U.S. adults have high blood pressure, according to new statistics from the American Heart Association. That’s nearly half of all adults in the United States. As reported in the AHA’s Heart Disease and Stroke Statistics – 2018 Update, published in January 2018, Dr. Paul Muntner, co-chair of the group that wrote the document, said “with the aging of the population and increased life expectancy, the prevalence of high blood pressure is expected to continue to increase.”
“Uncontrolled hypertension increases the risk of stroke, heart attack, heart failure, dementia, kidney disease, eye problems (retinopathy), erectile dysfunction and diabetes. The good news is that hypertension can be prevented and controlled with healthy lifestyle strategies, and, when required, medication for additional control. With DIAGNOS’ new HTA application, we can measure the cumulative damage of hypertension on the retinal microcirculation. The retina provides a window and an easy way to look into your body circulation,” said Dr. Reid Maclellan, member of the Board of Directors, DIAGNOS.
“Our test will address one of the more pressing needs in cardiology and in the preventive medicine field to decrease the socioeconomic burden and complication cost of hypertension. This approach should complement public actions to reduce community risk factor levels and promote a healthier lifestyle. The simplicity and effectiveness of our solution will greatly help decrease the risk of stroke and heart attack,” said André Larente, CEO, DIAGNOS.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
For further information, please contact:
Mr. André Larente, President |
DIAGNOS Inc. |
Tel: 450-678-8882 ext. 224 |
alarente@diagnos.ca |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
DIAGNOS Announces the Opening of a Screening Clinic at Chaparral’s Health Management Wellness Center for Medicare Beneficiaries
Momentum Public Relations
Press Release: March 14 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the opening of a third eye screening clinic in California located at Chaparral Medical Group Health Management Wellness Center.
In 2010, Medicare launched an annual benefit to all their members at Chaparral’s Health Management Wellness Center. The goal is to help promote preventive care methods, emphasizing on how to prevent disease instead of treating disease. With that, Chaparral Medical Group has decided it will automatically include eye screening using our CARA platform for diabetic and pre-diabetic patient at their annual visit.
“Chaparral is introducing AI to enhance the overall value of the annual health examination to Medicare members by encompassing CARA as an additional screening test for the annual wellness program. It is estimated that Medicare currently has 44 million beneficiaries enrolled in the Medicare program, some 15 percent of U.S. population. Having Chaparral Medical Group as a trusted partner will help to deploy faster while meeting all the industry requirements,” said Yves-Stephane Couture, VP sales at DIAGNOS.
“By adding eye screening with retina anomalies detection, we are broadening our study for annual wellness visits. As DIAGNOS continues to develop new algorithms and detect more illness, it will significantly help us to prevent disease evolution and take early action. We are proud to use DIAGNOS’ state of the art technology and to benefit from the Artificial Intelligence in our daily fight against diseases and we look forward to using them at the Health Management Centre,” said Dr. Jeereddi Prasad MD, Diabetes Specialist, President, and Medical Director of Chaparral Medical Group.
About Chaparral Medical Group
Chaparral Medical Group is a 80 physicians multi-specialty group serving the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group’s clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population Southern California. They have been serving the community since 1978 and their unwavering commitment to patient care and physician work satisfaction are what have driven them to become the most trusted and relied-upon group of physicians in their area.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on our FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Daniel Renaud or Thomas Renaud, Managing Directors |
DIAGNOS Inc. | Arrowhead Business and Investment Decisions, LLC |
Tel: 450-678-8882 ext. 224 | Tel: +1 212 619 6889, ext. 7010 |
alarente@diagnos.ca | diagnos@arrowheadbid.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos